JL--thanks for these posts. Very interesting observations.
Why do you think AMRN management is not communicating this to Wall Street in terms of getting out in front with this story and considering the share price decimation and explaining that there is still much value here despite the Marine patent loss?
Absurd...any prescription written for V can be dispensed as generic V if available whether for marine or CVD unless specifically saying dispense as written...this is why AMRN won't promote V if the loose appeal.
News 
Market Data 
Discover 
